• LAST PRICE
    15.1500
  • TODAY'S CHANGE (%)
    Trending Up0.5100 (3.4836%)
  • Bid / Lots
    15.0400/ 2
  • Ask / Lots
    15.1500/ 1
  • Open / Previous Close
    14.8300 / 14.6400
  • Day Range
    Low 14.8300
    High 15.1500
  • 52 Week Range
    Low 9.9100
    High 64.0000
  • Volume
    12,004
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 14.64
TimeVolumeTSVT
09:32 ET241614.94
09:34 ET10014.94
09:36 ET191614.99
09:38 ET341115.08
09:39 ET20015.07
09:43 ET10015.14
09:45 ET38415.12
09:57 ET10015.145
09:59 ET10015.15
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTSVT
2Seventy Bio Inc
487.4M
-1.5x
---
United StatesGTHX
G1 Therapeutics Inc
497.1M
-3.2x
---
United StatesTARS
Tarsus Pharmaceuticals Inc
432.7M
-6.4x
---
United StatesIMTX
Immatics NV
579.6M
46.5x
---
United StatesATAI
ATAI Life Sciences NV
508.1M
-2.8x
---
United StatesSLGC
Somalogic Inc
532.0M
-6.4x
---
As of 2022-10-04

Company Information

2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development and commercialization of transformative treatments for cancer. The Company is advancing multiple clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia, and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as multiple preclinical programs, including bbT4015, an engineered chimeric antigen receptor (CAR) T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb (BMS), the Company is delivering ABECMA to multiple myeloma patients in the United States for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and a cyclic ADP ribose hydrolase (anti-CD38) monoclonal antibody.

Contact Information

Headquarters
60 Binney StreetCAMBRIDGE, MA, United States 02210
Phone
339-499-9300
Fax
302-636-5454

Executives

Independent Chairman of the Board
Daniel Lynch
President, Chief Executive Officer, Director
Nick Leschly
Chief Financial Officer
William Baird
Chief Operating Officer
Nicola Heffron
Chief Scientific Officer
Philip Gregory

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$487.4M
Revenue (TTM)
$57.2M
Shares Outstanding
37.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-10.34
Book Value
$15.26
P/E Ratio
-1.5x
Price/Sales (TTM)
8.5
Price/Cash Flow (TTM)
---
Operating Margin
-526.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.